Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is well positioned for success with a strong presence in the commercial market through its marketed Korlym tablets and growing sales force targeting the large percentage of physicians treating PROC patients. With the recent FDA approval and addition to NCCN guidelines, as well as ongoing clinical trials in other oncology indications, there is significant potential for upside in the company's stock value. However, the company's stock may be subject to volatility due to potential pricing discounts for generic Korlym and potential execution risks, leading to a lower 12-month price target of $67 per diluted share and an increased discount rate of 12%.

Corcept Therapeutics is facing key competitor risks in the market for hypercortisolism treatment, with new alternative mechanisms targeting the Korlym approach to the disease. Additionally, the recent Court of Appeals decision that Teva's generic Korlym does not infringe on Corcept's patents further opens the market to potential competitors, likely leading to steeper discounts and a lower net price per patient. Furthermore, while Corcept's latest drug, Lifyorli, was approved for ovarian cancer ahead of schedule and may contribute significantly to total revenue in 2026, potential liver safety signals may impact its label and the drug remains vulnerable to competitor options such as Keytruda.